Gilead’s Trodelvy approved in metastatic urothelial cancerGilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. Share XGilead’s Trodelvy approved in metastatic urothelial cancerhttps://pharmaphorum.com/news/gileads-trodelvy-approved-in-metastatic-urothelial-cancer/
Akari begins late-stage trial of nomacopan for Bullous PemphigoidAkari Therapeutics is to begin a late-stage trial of nomacopan, its potential therapy for Bullous Pemphigoid, the rare Share XAkari begins late-stage trial of nomacopan for Bullous Pemphigoidhttps://pharmaphorum.com/news/akari-begins-late-stage-trial-of-nomacopan-for-bullous-pemphigoid/
Safety study pushes back phase 3 trial of Newron’s schizophrenia drugSwitzerland’s neurology specialist Newron must hold off starting a phase 3 study of its schizophrenia drug evenamide to Share XSafety study pushes back phase 3 trial of Newron’s schizophrenia drughttps://pharmaphorum.com/news/safety-trial-pushes-back-phase-3-trial-of-newrons-schizophrenia-drug/
FDA grew too close to Biogen during Alzheimer’s drug development, doctors sayThe FDA got too close to Biogen during the development of the Alzheimer’s drug aducanumab, according to its Share XFDA grew too close to Biogen during Alzheimer’s drug development, doctors sayhttps://pharmaphorum.com/news/fda-grew-too-close-to-biogen-during-alzheimers-drug-development-doctors-say/
Amgen buys inflammatory diseases drug firm Rodeo for up to $721mAmgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its Share XAmgen buys inflammatory diseases drug firm Rodeo for up to $721mhttps://pharmaphorum.com/news/acquisitive-amgen-buys-inflammatory-diseases-drug-firm-rodeo-for-up-to-721m/
Novo Holding launches latest call for antibiotic investment proposalsWith the focus on COVID-19 over the last year it’s easy to forget another deadly pandemic caused by Share XNovo Holding launches latest call for antibiotic investment proposalshttps://pharmaphorum.com/news/novo-holding-launches-latest-call-for-antibiotic-investment-proposals/
Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the companyFrom animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how Share XCulture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the companyhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/fujifilm-irvine-scientific-coo-cell-therapy-covid-vaccines/
Slaoui exits three more companies amid harassment falloutMoncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm Share XSlaoui exits three more companies amid harassment fallouthttps://pharmaphorum.com/news/slaoui-exits-three-more-companies-amid-harassment-fallout/
AZ issues revised efficacy figures for COVID-19 shotAstraZeneca has issued revised efficacy figures from the US trial of its COVID-19 vaccine following a complaint from Share XAZ issues revised efficacy figures for COVID-19 shothttps://pharmaphorum.com/news/az-issues-revised-efficacy-figures-for-covid-19-shot/
